Theravance Biopharma (TBPH) Cash from Operations (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly Cash from Operations of 73279000.0 for Q1 2026, up 70.26% year-over-year from 43039000.0 in Q1 2025, and up 1308.43% quarter-over-quarter from 6064000.0 in Q4 2025.
Theravance Biopharma (TBPH) Cash from Operations (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Cash from Operations for 14 consecutive years, with 73279000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 70.26% year-over-year to 73279000.0; the TTM figure through Mar 2026 stood at 268781000.0 (up 726.36% YoY), while the FY2025 annual figure was 238541000.0, up 2167.98% from the prior year.
- Cash from Operations advanced to 73279000.0 in Q1 2026 per TBPH's latest filing, from 6064000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 208074000.0 in Q2 2025 and bottomed at 26069000.0 in Q1 2022.
- Historically, Cash from Operations has averaged 15933117.65 across 5 years, with a median of 4415000.0 in 2024.
- On a YoY basis, Cash from Operations climbed as much as 4812.89% in 2025 and fell as far as 572.28% in 2025.
- Theravance Biopharma's Cash from Operations stood at 54913000.0 in 2022, then tumbled by 101.56% to 854000.0 in 2023, then fell by 5.62% to 902000.0 in 2024, then plunged by 572.28% to 6064000.0 in 2025, then soared by 1308.43% to 73279000.0 in 2026.
- Business Quant data shows TBPH's Cash from Operations at 73279000.0 in Q1 2026, 6064000.0 in Q4 2025, and 6508000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | -6.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.97 Mn |
| Jun 30, 2026 | -6.97 Mn |
| Mar 31, 2026 | 73.28 Mn |
| Mar 31, 2026 | 73.28 Mn |
| Dec 31, 2025 | -6.06 Mn |
| Dec 31, 2025 | -6.06 Mn |
| Sep 30, 2025 | -6.51 Mn |
| Sep 30, 2025 | -6.51 Mn |
| Jun 30, 2025 | 208.07 Mn |
| Jun 30, 2025 | 208.07 Mn |
| Mar 31, 2025 | 43.04 Mn |
| Mar 31, 2025 | 43.04 Mn |
| Dec 31, 2024 | -902,000.00 |
| Dec 31, 2024 | -902,000.00 |
| Sep 30, 2024 | -5.20 Mn |
| Sep 30, 2024 | -5.20 Mn |
| Jun 30, 2024 | -4.42 Mn |
| Jun 30, 2024 | -4.42 Mn |
| Mar 31, 2024 | -1.02 Mn |
| Mar 31, 2024 | -1.02 Mn |